Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting
The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor.